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Abstract
Systemic Lupus Erythematosus is a disease that manifests in many different ways. The cause of lupus still remains elusive.
However, many of the pathologies associated with the disease as well as the disease process have been described. The pathophysiology of the disease as well as its effects on specific patient groups will be discussed below. More specifically, Systemic Lupus’
effect on pregnancy with current diagnostic and treatment modalities will be the focus of this paper.
Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease that is common and affects around 400 per
100,000 people in certain populations. SLE mainly affects
African or Hispanic women, especially during their reproductive years. The telltale sign of SLE is the production of
autoantibodies, specifically antinuclear antibodies (ANAs).
The most common method for detecting these ANAs is
indirect immunofluorescence, which can recognize antibodies that bind to nuclear antigens, such as DNA, RNA,
and proteins. Besides ANAs, patients with SLE have a variety of other autoantibodies that fight against red blood
cells, platelets, and lymphocytes. The causes of SLE, like
most autoimmune diseases, are unknown. However, genetic, environmental, and immunological factors seem to
play a role (Kumar, et. al. 2018). Fatigue, joint pain, and rash
are the most common symptoms of SLE. SLE is unique
because of the disease’s ability to appear and disappear
called flares. Flares are known to occur during rapid hormonal changes, as occurs in pregnancy. For women with
SLE, pregnancy is a major concern. Pregnancy is a highrisk time for SLE patients because flares during pregnancy
may be related to increased irreversible organ damage
(Ateka-Barrutia, Khamashta, 2013). The risk of flare
during pregnancy depends on the disease activity 6-12
months before conception; the risk is higher in those
who have had repeated flares preconception. Therefore,
women living with SLE who are thinking about conceiving
should consult their rheumatologist prior to conceiving,
so that they can monitor disease activity to ensure the
best outcome for mother and baby.
Methods
The data in this paper was compiled using Pubmed,
ProQuest, and Google Scholar. PubMed and Proquest
were accessible through Touro College’s Online Library
system. Key terms used to search were: “SLE pregnancy”,
“SLE”, “hydroxychloroquine”, and “autoimmune diseases”.
Discussion
Pathogenesis of Systemic Lupus Erythematosus
The principle deficiency in SLE is the failure of the mechanisms that maintain self-tolerance. Although the cause(s)
of the lack of self-tolerance remains unknown, there are
several genetic, environmental, and immunological factors
that seem to play a role.

There is a lot of evidence that suggests a genetic predisposition to SLE. Family members have a higher risk of
developing SLE, and even twenty percent of uninfluenced
first-degree family members have autoantibodies. The
concordance of SLE in monozygotic twins is twenty-five
to fifty percent and around five percent in dizygotic twins,
which suggests that genetic factors play a crucial role in
the predisposition of SLE (Kumar, et. al. 2018). The above
said indicates a polygenic inheritance of the disease- it
is approximated that at least 4 susceptibility genes are
required in order to develop SLE (Schur, 1995).
Studies reveal that SLE susceptibility involves human
leucocyte antigen (HLA) class II gene polymorphisms. In
patients from different backgrounds, a relation between
HLA DR2 and DR3 with SLE is a regular finding with an
odds ratio for developing SLE of roughly 2 to 5 (Pisetsky,
1997). Which means, a person with HLA DR2 and DR3 are
two to five times more likely to develop SLE than a person
without HLA DR2 and DR3. HLA class II genes have also
been linked to the presence of some autoantibodies, for
example: anti-Sm, anti-Ro, anti-La, anti-nRNP, and anti-DNA
antibodies. HLA class III genes, specifically those “encoding
complement components C2 and C4”, are major contributors in the development of SLE. Patients with homozygous C4A null alleles, regardless of their background, have
a higher risk of having SLE. Additionally, SLE is connected
to inherited deficiencies of C1q, C1r/s, and C2 (Mok, Lau,
2003). A reduction in complement activity could encourage SLE susceptibility by damaging the neutralization and
removal of foreign and self-antigens. “When the antigen
burden overwhelms the clearance capacity of the immune
system, autoimmunity may ensue” (Mok, Lau, 2003). Other
polymorphic genes have been linked to SLE such as: tumor
necrosis factor alpha, interleukin six, the T cell receptor,
CR1, Fc gamma RIIA and Fc gamma RIIIA, immunoglobulin Gm and Km allotypes, and heat shock protein seventy
(Sullivan, 2000). Nonetheless, in majority of cases, consistent results were not reported in studies of patients from
different ethnic backgrounds.
Although genetic factors play a crucial role in regard to
the predisposition towards SLE, the start of the disease
stems from environmental triggers. Infectious agents,
such as bacterial DNA/endotoxins and retroviruses, may
cause particular reactions by molecular imitation and disrupt immunoregulation. Viruses might set off or induce a
flare in lupus by harming tissues to release autoantigens,
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triggering B cells, and inducing SLE by molecular imitation. But, viral findings have not been consistent in the
tissues of people with lupus (Herrmann, et. al. 1996).
Therefore, there is not enough evidence to defend that
any one infectious agent causes SLE. Certain diet choices, like alfalfa sprouts and high intake of saturated fats,
influences the making of inflammatory mediators. Alfalfa
sprouts contain L-canavanine which has been associated with the development of SLE-like symptoms (Prete,
1985). Procainamide, hydralazine, chlorpromazine, isoniazid, phenytoin, and penicillamine are drugs that alter
“cellular responsiveness and immunogenicity of self-antigens” (Mok, Lau, 2003). Procainamide and hydralazine
are aromatic amines or hydrazines, and they can cause
an SLE-like disorder (Adams, Mongey, 1994). Ultraviolet
light may aggravate SLE in many patients. UV light can
trigger inflammation, promote cellular apoptosis, and induce tissue damage. Exposure to the sun’s light causes
and aggravates SLE. Exposure of skin to ultraviolet light
changes the location and/or chemistry of DNA, Ro, and
nRNP antigens, and also amplifies their immunogenicity.
Recent studies have shown that ultraviolet light causes
the apoptosis of human keratinocytes, which brings about
the development of clusters on the exterior of dying cells,
that hold nuclear and cytoplasmic antigens. This supplies
a method for the exposure of self-antigens to the immune system and evokes autoimmunity (Mok, Lau, 2003).
To summarize: UV light and other environmental factors cause the apoptosis of cells. Insufficient removal of
the nuclei of these cells leads to a large burden of nuclear antigens. Underlying abnormalities in B lymphocytes
and T lymphocytes are accountable for flawed tolerance,
and, as a result, self-reactive lymphocytes live on and stay
functioning. Said lymphocytes are activated by nuclear
self-antigens, and antibodies are made to fight the antigens. Complexes of the antigens and antibodies stick
to Fc receptors on dendritic cells and B cells and might
be engulfed. The nucleic acid elements engage toll-like
receptors (TLRs) and trigger B cells to create more autoantibodies. TLR stimuli also trigger dendritic cells to
make interferons and other cytokines, which intensifies
the immune response and induces more apoptosis. The
overall result is a “cycle of antigen release and immune
activation resulting in the production of high-affinity autoantibodies” (Kumar, et. al. 2018).
Autoantibodies
The number one hallmark, and the number one concern,
of lupus is the production of autoantibodies. These antibodies attack the patient’s own molecules found in the
cytoplasm, nucleus, cell surface, and soluble molecules like
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coagulation factors and IgG. Antinuclear antibodies are
found in more than ninety five percent of SLE patients; anti-double stranded DNA (ds-DNA) and anti-Sm antibodies
are specific for SLE and not found in patients with other
autoimmune diseases, making them very important in the
diagnosis (Tan, et. al. 1982). ANAs can be divided into 4
groups: antibodies to DNA, antibodies to nucleolar antigens, antibodies to nonhistone proteins bound to RNA,
and antibodies to histones. Additionally, many other autoantibodies are found in patients with SLE. These autoantibodies attack lymphocytes, platelets, and red blood cells.
Thirty to forty percent of SLE patients have anti-phospholipid antibodies. These patients have complications secondary to excessive clotting (Kumar, et. al. 2018).
Symptoms of SLE
SLE is a chronic disease, meaning that the disease is long
lasting, in this case specifically, the disease waxes and
wanes. The symptoms and the effects on daily life of SLE
vary, however, there are some that were seen in nearly all patients. A group of patients were selected from
6 rheumatology practices that were spread across the
United States between May and July 2014. These patients
were between the ages of eighteen and seventy-five and
had a clinical diagnosis of lupus. Ninety eight percent
of patients reported they felt fatigue, ninety three percent reported joint pain, eighty eight percent reported a
rash, eighty percent reported swelling of feet, legs, fingers,
or hands and joint stiffness. Because SLE is chronic it
has major effects on a patient’s daily life and activities.
Sixty one percent of those interviewed had difficulty
with housework, thirty nine percent had difficulty driving
and sleeping, and twenty two percent had difficulty caring for children. Sixty two percent of the patients who
participated in this study were not working outside the
home; ninety one percent said that this was caused by
SLE (Mathias, et. al. 2018).
Hormonal Effects on SLE
Lupus is primarily a female disease; it is “characterized by a
9:1 female to male ratio of disease incidence” (Weckerle,
Niewold, 2011). Generally, SLE occurs between puberty
and menopause, the reproductive age range (15:1 ratio).
Occurrence of SLE before puberty and after menopause
is uncommon. Furthermore, patients with a hypergonadotrophic disorder, namely Klinefelter’s Syndrome, are
prone to lupus as well. From these observations, it is assumed that endogenous sex hormones play a major role
in lupus (Mok, Lau, 2003).
Epidemiological studies show a connection between
the use of exogenous estrogens and the emergence of
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lupus. The Nurses’ Health Study revealed that hormonal
replacement therapy and the use of oral contraceptive
pills have an association with an increased chance of
developing SLE (Sanchez-Guerrero, et. al. 1997). Lupus
improvement was observed in patients who had gone
through menopause or an oophorectomy. Conversely,
lupus flares mainly occur during hormonal changes, such
as pregnancy, exogenous estrogen administration, puerperium, and ovulation during IVF (Mok, Wong, 2001). Many
patients exhibit disease flares during the second half of
their menstrual cycle, this has been attributed to the midcycle estrogen surge. Additionally, patients who develop
lupus after the age of fifty were reported to have a milder
disease and less significant organ involvement. All these
observations are helpful in explaining and understanding
why pregnancy for SLE patients is extremely difficult.
Pregnancy and SLE Pregnancy
Healthy, normal pregnancy causes the body to go through
many physiological changes; these changes may influence
rheumatic disease expression. Most organ systems go
through some level of change during pregnancy. The glomerular filtration rate goes up by fifty percent during a
normal pregnancy. Subsequently, women with preceding
proteinuria might be expected to have a noticeable rise in
urinary protein excretion in the 2nd and 3rd trimesters.
There is also an expected thirty-fifty percent elevation in
intravascular volume; women who have cardiac or renal
compromise might not endure this well. Additionally,
blood counts are usually different during pregnancy.
Anemia is usual due to hemodilution, and in eight percent
of uncomplicated pregnancies there is an occurrence of
thrombocytopenia. The chance of venous thromboembolism increases by fivefold during normal pregnancy,
because of the prothrombotic state that pregnancy creates along with compression by the expecting uterus and
venous stasis (Sammaritano, 2016).
In normal pregnancy, the mother’s immune system is
altered in order to ensure fetal health and survival: immunoglobulin secretion rises, cell mediated immunity
decreases, and pregnancy-specific proteins work to inhibit lymphocyte function (Branch, Wong, 2014). General
immunosuppression would reduce maternal resistance
against infection, so instead, there is an activation in
the maternal immune system during pregnancy of immune-modulatory molecules and immunocompetent
cells (Ostensen, Clowse, 2013). Cytokines and chemokines manage these immunocompetent cells with T helper
cells; cytokines are an important factor in supporting successful pregnancy. The Th1/Th2 cytokine shift is a crucial
immunological change that occurs during pregnancy. Th2

includes numerous interleukins which trigger antibody
synthesis and humoral immunity. In pregnancy a prevalence of the Th2 response might be anticipated, and since
lupus is predominantly a Th2-mediated disorder, aggravation of the disorder is more likely (de Jesus, et. al. 2015).
Pregnancy is high-risk for women with SLE, because
disease flares during pregnancy have been linked to
organ damage. Therefore, it is recommended that every
woman with lupus should receive a preconception evaluation which should assess organ damage related to lupus,
medications, and disease activity. If a patient is taking
medications for lupus that have adverse effects on pregnancy, it is suitable for the patient to change to a lower
risk medication (Flint, et. al. 2016). Additionally, for the
best pregnancy outcome and for the mother’s safety, it is
advised that women with SLE should conceive during a
time of inactive disease. Disease flares during pregnancy
have been linked to disease activity six to twelve months
before conception. Lupus flare within 6 months prior
to conception has been linked to a significant rise in the
chance of flare during pregnancy and a fourfold increase
in pregnancy loss (Clowse, 2007).
Pregnancy for women with lupus has been linked
to: risk of flare, preeclampsia, hypothyroidism, stroke,
preterm birth, hypertension, pre-gestational diabetes,
caesarean section, placental deficiencies leading to intrauterine growth restriction (IUGR), pregnancy loss, and
even death. The Danish National Registry stated that maternal complications were found in fifty percent of lupus
pregnancies (Jakobsen, et. al. 2015). A recent study observed thirteen thousand five hundred and fifty-five SLE
pregnancy deliveries. Twenty five percent of SLE pregnancies were delivered preterm, meaning the pregnancy was
shorter than thirty-seven weeks (Yan Yuen, et. al. 2008).
Six to thirty five percent of babies were born small for
gestational age. One in five lupus pregnancies ended in
pregnancy loss (compared with one in ten from controls),
with a four to six-fold increased likelihood of stillbirths
compared with controls (Clark, et. al. 2003). Disease
activity within six months before conception has been
linked to an increased rate of fetal loss. Patients with
anti-dsDNA antibodies have the highest risk for preterm
birth and pregnancy loss. Patients with lupus have a three
to four-fold increased chance of developing preeclampsia. Antiphospholipid antibodies are found in thirty-forty
percent of SLE patients and have been linked to negative
obstetric outcomes. Women with aPL antibodies have
an increased chance of developing IUGR, preeclampsia,
preterm birth, and fetal loss (Smyth, et. al. 2010).
The PROMISSE study observed three hundred and eighty
five women with lupus and found that fifteen percent of
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them experienced a mild flare, whereas five percent experienced an extreme flare. Sixty percent of women with
active SLE prior to conception experienced flares during
pregnancy, however, only ten percent of women with inactive SLE prior to conception experienced flares during
pregnancy (Buyon, et. al. 2015). A study conducted in
Sweden observed five hundred and fifty one first singleton
births to patients with lupus and assessed their outcomes
in comparison to the general population. This study included twelve thousand eight hundred and forty seven normal pregnancies, one hundred and ninety eight pre-lupus
women, sixty five women who were first diagnosed with
lupus zero-two years after giving birth, and one hundred
and thirty three women who were diagnosed two-five
years postpartum. Compared to those who were diagnosed with lupus two-five years after their first pregnancy,
those with lupus during their first pregnancy, or diagnosed
soon after, had the highest risk of poor clinical outcomes.
Twenty six percent of women who were diagnosed with
lupus zero-two years after giving birth had preeclampsia
during pregnancy, thirteen percent of women who were
diagnosed two-five years after giving birth had preeclampsia during pregnancy, and sixteen percent of women who
had lupus while pregnant had preeclampsia; while only
approximately five percent of women without lupus had
preeclampsia (Arkema, et. al. 2016).
Over the last forty years some of the adverse pregnancy outcomes have improved. A study compared lupus
pregnancies from forty years earlier to their current pregnancy group, which consisted of eighty three pregnant
women. The rate of pregnancy loss decreased dramatically from forty percent to seventeen percent, compared
with the general population rate of sixteen percent. On
the other hand, the preterm delivery rate did not change
dramatically. It only dropped from thirty seven percent to
thirty two percent versus nine to twelve percent preterm
delivery rate of the general population (Clark, et. al. 2005).
A Norwegian study analyzed pregnant women with connective tissue diseases, including lupus, over the last four
decades. Although maternal and fetal complications were
more prevalent in lupus patients compared to the general population, the number of births did increase and the
rate of C-sections, low birth weight infants, and preterm
births decreased (Wallenius, et. al. 2015).
Effects of SLE on the Baby
Complications during pregnancy can impact fetal and neonatal outcomes. There is an increased chance of preterm
delivery, preeclampsia, fetal loss, and low birth weight babies in women with lupus. When maternal autoantibodies,
aPL antibodies, anti-Ro/SS-A and anti-La/SS-B antibodies
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are present there are more precise risks. The presence of
aPL antibodies has been commonly linked to prematurity
and intrauterine growth restriction.
Anti-Ro or anti-La antibodies are found in around thirty percent of SLE
patients. These autoantibodies can cross the placenta by
active transport between the sixteenth and thirtieth weeks
of pregnancy. Babies who are born to women with anti-Ro/
SS-A and anti-La/SS-B antibodies have an increased risk of
having neonatal lupus erythematosus (Sammaritano, 2016).
These autoantibodies have been linked to the development
of congenital complete heart block and noncardiac neonatal lupus erythematosus expressions such as: transaminitis, reversible thrombocytopenia, and photosensitive rash
(Brito-Zero’n, et. al. 2014).
Congenital complete heart block is the most serious condition linked to anti-Ro/SS-A and anti-La/SS-B
antibodies and occurs in approximately two percent of
babies born to mothers with these antibodies. If the
mother previously had a child with congenital heart block,
then the risk for the second child having it increases to
eighteen percent; if the mother previously had two children with congenital heart block then the risk increases
to fifty percent (Brucato, et. al. 2001). In more than eighty
percent of children with congenital heart block the mother had anti-Ro or anti-La antibodies. Typically, congenital
heart block develops between sixteen and twenty four
weeks of pregnancy, and it can be recognized by low fetal
heart rate which is less than sixty beats per minute. AntiRo and anti-La antibodies attack the myocardium and
fetal atrioventricular node. This causes immune mediated
inflammation and fibrosis in tissues that are affected, resulting in various levels of heart block or cardiomyopathy
(Llanos, et. al. 2012). The risk of death for babies affected
is around ten-twenty percent and most of those who survive require a permanent pacemaker.
Various treatments for congenital heart block have
been tried. Because of their capability to diffuse across
the placenta, fluorinated steroids are used for cases that
involve myocarditis, hydrops, or incomplete heart block
due to its potential to reverse the affects (Friedman, et.
al. 2009). Exposure to hydroxychloroquine throughout
pregnancy might lower the chances of development of
congenital heart block (Izmirly, et. al. 2012).
Treatments/Management of SLE Pregnancy
Firstly, patients with lupus who are considering pregnancy
should be closely followed by their rheumatologist and
obstetrician. Lupus should be quiescent, and the patient
should be on medications that are low risk for approximately 6 months before conception. Recent studies
show that antimalarial medications are beneficial for the
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mother and baby and have few side effects, and therefore should be taken throughout pregnancy. In one study
of one hundred and eighteen lupus pregnancies, poor
pregnancy outcomes were dramatically reduced in the
women who were taking hydroxychloroquine. “Preterm
delivery rates were 15.8% in that group versus 44.2% in
untreated patients, and rates of IUGR were 10.5% versus 28.6%” (Leroux, et. al. 2015). In a different study,
women who stopped taking hydroxychloroquine suffered
remarkably more lupus activity than women who continued hydroxychloroquine (Clowse, et. al. 2006). The
use of hydroxychloroquine throughout pregnancy in
patients with lupus minimizes the number of flares and
hypertensive disorders. Hydroxychloroquine is safe to
use during pregnancy, and there have been no “reported
malformations, growth restriction and ocular, auditory, or
neurological toxicity in exposed fetus” (Ruiz-Irastorza,
Khamashta, 2011). Hydroxychloroquine is secreted in
breast milk; however, there were no reports of negative
effects in children who were breastfed.
In the case of disease reactivation during pregnancy, corticosteroids are usually used. Since fluorinated corticosteroids diffuse across the placenta, they should not be taken
during pregnancy. On the other hand, non-fluorinated
corticosteroids, (prednisone, prednisolone, methylprednisolone, hydrocortisone) are broken down by placental 11
beta-hydroxysteroid dehydrogenase, and only ten percent
of drug dosage crosses the placenta. That said, non-fluorinated corticosteroids are connected to various complications such as diabetes, preeclampsia, and hypertension;
therefore, low doses are recommended (prednisone<7.5
mg/day) (Ruiz-Irastorza, et. al. 2012). A dose of above ten
mg/day of prednisone has been linked to a higher chance
of developing dyslipidemia, arterial hypertension, maternal
hyperglycemia, and fluid retention. Non-fluorinated corticosteroids are only slightly passed into breast milk and
is permitted during breastfeeding. However, if the dose is
high then women should wait four hours after taking the
corticosteroid to breastfeed.
Most immunosuppressive medications are stopped during
pregnancy and breastfeeding, except azathioprine in doses
up to two and a half mg/kg/day, cyclosporin, and tacrolimus.
Although cyclosporin has been deemed safe to use during
pregnancy, it has been linked to an increased chance of preeclampsia, hypertension, and gestational diabetes (AtekaBarrutia, Khamashta, 2013). Mycophenolate mofetil, methotrexate, and cyclophosphamide are not safe to use during
pregnancy and should be switched to safer drugs.
NSAIDs are overall safe to use throughout pregnancy if they are limited to short term usage. However,
long term use of NSAIDs have been linked to cardiac

and renal failure, fluid overload, and hypertension in the
mother, and renal disorders and oligohydramnios in the
fetus. The use of these medications should only take
place at the end of pregnancy, after thirty weeks of gestation (Ostensen, et. al. 2006).
Antiplatelets and anticoagulants are also used to treat
lupus. The use of low-dose aspirin (75-100 mg/day) and
dipyridamole is safe to use during pregnancy. Aspirin can
be used even throughout labor or epidural anesthesia to
decrease the chance of hemorrhagic issues. Since heparins do not diffuse across the placenta, they are safe to
use throughout pregnancy and breastfeeding. However,
warfarin is damaging to the fetus during organogenesis
(the first six-ten weeks of pregnancy) and therefore
should not be taken during this timeframe (Ostensen, et.
al. 2006). Patients taking these medications should be
switched to heparin when pregnancy is confirmed.
Conclusion
Systemic Lupus Erythematosus is a disease with varying
severity in the population, but one that can have devastating effects on mother and baby. Advances in the understanding of the disease as well as treatment and prevention of flare ups have allowed women with lupus to have
successful and healthy pregnancies with favorable outcomes. It is imperative however, that women with lupus
seek guidance from their rheumatologist and obstetrician
and focus on prenatal care for the best possible outcome
for mother and baby.
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